2019冠状病毒病与妊娠:产科医生需要了解的信息
本文综述了COVID-19在妊娠期的影响,并借鉴SARS和MERS的数据。2项报告描述18例妊娠合并COVID-19,均为孕晚期感染,临床表现与非妊娠成人相似,部分出现胎儿窘迫和早产,除2例外均为剖宫产,未见宫内传播证据。目前无FDA批准的特异性治疗,管理应包括早期隔离、感染控制、氧疗、避免液体超负荷及多学科团队协作。
要点
- 妊娠合并COVID-19的临床特征与非妊娠成人相似,但可能增加妊娠并发症风险。
- SARS孕妇病死率达25%,机械通气风险是非孕妇的3倍;MERS孕妇病死率23%。
- 管理原则包括早期隔离、感染控制、氧疗、避免液体超负荷及多学科协作。
核心结论
- COVID-19可能增加妊娠并发症风险,管理应在具备密切母胎监测的医疗机构进行。
- 目前无COVID-19特异性治疗获批,临床医生应持续关注CDC最新信息。
研究设计与样本
- 综述,总结COVID-19、SARS和MERS在妊娠期的现有数据。
- COVID-19妊娠数据来自2项报告共18例孕晚期感染。
- SARS妊娠数据来自最大系列12例,MERS妊娠数据来自13例病例报告。
主要发现
- 18例COVID-19孕妇均为孕晚期感染,临床表现与非妊娠成人相似,部分出现胎儿窘迫和早产。
- 18例中除2例外均为剖宫产,未见宫内传播证据。
- SARS孕妇病死率25%,并发症包括ARDS 4例、DIC 3例、肾衰竭3例、继发细菌性肺炎2例、脓毒症2例。
- SARS孕妇机械通气可能性是非妊娠妇女的3倍;7例孕早期感染中4例自然流产,5例孕24周后感染中4例早产。
- MERS孕妇13例中2例无症状,3例(23%)死亡,2例胎死宫内,2例早产,未见宫内传播证据。
关键数值与推荐
- COVID-19潜伏期约5天(范围2-14天)。
- 住院患者平均年龄49-56岁,三分之一至一半有基础疾病,男性占54-73%。
- 住院患者ARDS发生率为17-29%,总体病死率约1%。
临床怎么用
- 管理原则包括早期隔离、积极感染控制、氧疗、避免液体超负荷、考虑经验性抗生素、病毒及合并感染检测、胎儿及宫缩监测。
- 进行性呼吸衰竭应早期机械通气,个体化分娩计划,多学科团队协作。
- 临床医生应持续关注CDC网站获取最新信息。
局限性
- 妊娠合并COVID-19的数据有限,仅基于18例孕晚期感染。
- SARS和MERS在妊娠期的数据稀少。
- 早期数据可能高估COVID-19病死率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 is an emerging disease with a rapid increase in cases and deaths since its first identification in Wuhan, China, in December 2019. Limited data are available about coronavirus disease 2019 during pregnancy; however, information on illnesses associated with other highly pathogenic coronaviruses (ie, severe acute respiratory syndrome and the Middle East respiratory syndrome) might provide insights into coronavirus disease 2019's effects during pregnancy. Coronaviruses cause illness ranging in severity from the common cold to severe respiratory illness and death. Currently the primary epidemiologic risk factors for coronavirus disease 2019 include travel from mainland China (especially Hubei Province) or close contact with infected individuals within 14 days of symptom onset. Data suggest an incubation period of ∼5 days (range, 2-14 days). Average age of hospitalized patients has been 49-56 years, with a third to half with an underlying illness. Children have been rarely reported. Men were more frequent among hospitalized cases (54-73%). Frequent manifestations include fever, cough, myalgia, headache, and diarrhea. Abnormal testing includes abnormalities on chest radiographic imaging, lymphopenia, leukopenia, and thrombocytopenia. Initial reports suggest that acute respiratory distress syndrome develops in 17-29% of hospitalized patients. Overall case fatality rate appears to be ∼1%; however, early data may overestimate this rate. In 2 reports describing 18 pregnancies with coronavirus disease 2019, all were infected in the third trimester, and clinical findings were similar to those in nonpregnant adults. Fetal distress and preterm delivery were seen in some cases. All but 2 pregnancies were cesarean deliveries and no evidence of in utero transmission was seen. Data on severe acute respiratory syndrome and Middle East respiratory syndrome in pregnancy are sparse. For severe acute respiratory syndrome, the largest series of 12 pregnancies had a case-fatality rate of 25%. Complications included acute respiratory distress syndrome in 4, disseminated intravascular coagulopathy in 3, renal failure in 3, secondary bacterial pneumonia in 2, and sepsis in 2 patients. Mechanical ventilation was 3 times more likely among pregnant compared with nonpregnant women. Among 7 first-trimester infections, 4 ended in spontaneous abortion. Four of 5 women with severe acute respiratory syndrome after 24 weeks' gestation delivered preterm. For Middle East respiratory syndrome, there were 13 case reports in pregnant women, of which 2 were asymptomatic, identified as part of a contact investigation; 3 patients (23%) died. Two pregnancies ended in fetal demise and 2 were born preterm. No evidence of in utero transmission was seen in severe acute respiratory syndrome or Middle East respiratory syndrome. Currently no coronavirus-specific treatments have been approved by the US Food and Drug Administration. Because coronavirus disease 2019 might increase the risk for pregnancy complications, management should optimally be in a health care facility with close maternal and fetal monitoring. Principles of management of coronavirus disease 2019 in pregnancy include early isolation, aggressive infection control procedures, oxygen therapy, avoidance of fluid overload, consideration of empiric antibiotics (secondary to bacterial infection risk), laboratory testing for the virus and coinfection, fetal and uterine contraction monitoring, early mechanical ventilation for progressive respiratory failure, individualized delivery planning, and a team-based approach with multispecialty consultations. Information on coronavirus disease 2019 is increasing rapidly. Clinicians should continue to follow the Centers for Disease Control and Prevention website to stay up to date with the latest information (https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html).
引用
- Rasmussen SA, Smulian JC, Lednicky JA, et al. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol. 2020. PMID: 32105680. doi:10.1016/j.ajog.2020.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。